Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

Stéphane Champiat MD, PhD, assistant professor, Drug Development Department, Gustave Roussy Cancer Campus, discusses early efficacy seen with the combination of SOT101 and pembrolizumab (Keytruda) in solid tumors.

The phase 1 AURELIO-03 trial explored the use of SOT101 and pembrolizmab patients with solid tumors. AURELIO-03 observed safety and tolerability of SOT101, and the study investigated the recommended phase 2 dose. Preliminary efficacy was also studied.

Preliminary efficacy of SOT101 monotherapy was reported in 2021, which showed that the agent demonstrated some activity in several different tumor types, Champiat says. Preliminary data from AURELIO-03 with SOT101 plus pembrolizumab showed the combination elicited responses in patients who were immuno-naive or immuno-pretreated, including primary and secondary refractory tumors, Champiat explains.

Specifically, 1 patient achieved a confirmed complete response, and 4 patients experienced partial responses, Champiat adds. Of 16 patients enrolled, 12 had a response or stable disease, Champiat concludes.